Amit Tirosh
@tiroshamit.bsky.social
Privileged to take part in the 1st #VHL Alliance Research Forum in Charlotte, NC. Together, we explored future opportunities in VHL #CancerResearch.
Thank you, VHL Alliance and the Rath Family, for this inspiring meeting! We will continue studying VHL- #PNET and #PPGL! 🚀
#RareDisease #Oncology
Thank you, VHL Alliance and the Rath Family, for this inspiring meeting! We will continue studying VHL- #PNET and #PPGL! 🚀
#RareDisease #Oncology
November 15, 2025 at 7:42 PM
Privileged to take part in the 1st #VHL Alliance Research Forum in Charlotte, NC. Together, we explored future opportunities in VHL #CancerResearch.
Thank you, VHL Alliance and the Rath Family, for this inspiring meeting! We will continue studying VHL- #PNET and #PPGL! 🚀
#RareDisease #Oncology
Thank you, VHL Alliance and the Rath Family, for this inspiring meeting! We will continue studying VHL- #PNET and #PPGL! 🚀
#RareDisease #Oncology
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
November 1, 2025 at 4:03 PM
🎉 Excited to share our new publication!
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social
Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.
Potential therapeutic strategy for aggressive PNENs?
bit.ly/435pKBx
@endocancer.bsky.social